Combination BPH Therapy with Fexapotide Triflutate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for benign prostatic hyperplasia (BPH) are often less effective and cause unacceptable side effects, with hormonal therapies providing inconsistent results and limited reduction in prostatic volume and symptom improvement.
Innovation Solution
A combination therapy using fexapotide triflutate (FT) with a 5 α-reductase inhibitor and an alpha1-adrenergic receptor blocker, administered separately or together, to provide a significant improvement in International Prostate Symptom Scores (IPSS) compared to other combination therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormonal therapies are used to treat BPH, then treatment coverage is provided, but the effectiveness is inconsistent and side effects are unacceptable
Solution Approach 1:
The patent combines three different therapeutic agents with distinct mechanisms of action: fexapotide triflutate (a peptide that reduces prostatic volume through apoptosis), 5-ARI (which inhibits dihydrotestosterone synthesis), and alpha blockers (which relax smooth muscle in the prostate and bladder neck). This multi-component combination therapy addresses BPH through multiple pathways simultaneously, achieving synergistic improvement in IPSS scores while allowing for lower doses of each individual agent, thereby reducing side effects associated with monotherapy.
2Reliability
If combination therapy with multiple agents is used, then symptom improvement is enhanced, but treatment complexity increases
Solution Approach 1:
The patent divides the combination therapy into separate administrable components: fexapotide triflutate can be administered as an injection, while 5-ARIs and alpha blockers are administered orally. This segmentation allows each agent to be optimized for its specific route of administration and pharmacokinetic profile, simplifying the overall treatment regimen compared to requiring a single complex multi-functional agent. The separate administration also allows for flexible dosing schedules and easier management of side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy achieves a relative mean IPSS improvement of 40% to 100% compared to individual therapies and 45% to 400% compared to the average improvement of FT and the combination of a 5-ARI and an alpha blocker, offering superior symptom relief for BPH.
Implementation Method 1
FT has been shown to reduce prostate glandular cells through induction of apoptosis
Implementation Method 2
testosterone is irreversibly converted by 5α-reductase into the more potent androgen dihydrotestosterone... Inhibitors of 5 α-reductase have been found to inhibit prostatic growth
Implementation Method 3
an alpha1-adrenergic receptor blocker (alpha blocker)
Data Source
AI summary
Disclosed are methods of treating benign prostatic hyperplasia that include administering a composition containing at least Fexapotide Triflutate (FT), and subsequently administering one or more compositions containing a 5 α-reductase inhibitor (5-ARI) and an alpha1-adrenergic receptor blocker (alpha blocker). The methods provide dramatically improved mean IPSS values, when compared to the average mean IPSS of the individual actives alone, or when compared to the average mean IPSS of (a) the composition containing FT; and (b) the combination of 5-ARI and alpha blocker.